Tumor-infiltrating lymphocytes (TILs) are associated with survival benefits in HER2-positive and TNBC; however, in luminal/HER2-negative tumors, high TILs are negatively associated with survival benefits. The gene discussed is ERBB2; the disease is neoplasm.